Reata Pharmaceuticals (RETA) PT Raised to $85 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Reata Pharma (RETA) shares soar as FDA approves rare neurodegenerative disorder drug
March 1, 2023 8:40 AM ESTReata Pharma (NASDAQ: RETA) has more than doubled premarket after the U.S. Food and Drug Administration (FDA) approved SKYCLARYS to treat Friedreich's ataxia.
Reata shares are currently up more than 172% at $85 per share after closing Tuesday's session at $31.17.
SKYCLARYS has... More
